Global Psychiatric and Nervous Drugs Market Research Report 2024

Report ID: 1896901 | Published Date: Sep 2024 | No. of Page: 104 | Base Year: 2023 | Rating: 3.7 | Webstory: Check our Web story
1 Psychiatric and Nervous Drugs Market Overview
    1.1 Product Overview and Scope of Psychiatric and Nervous Drugs
    1.2 Psychiatric and Nervous Drugs Segment by Type
        1.2.1 Global Psychiatric and Nervous Drugs Sales Growth Rate Comparison by Type (2022-2028)
        1.2.2 Antidepressants
        1.2.3 Anti-anxiety
        1.2.4 Antipsychotic
        1.2.5 Mood Stabilizing
        1.2.6 Stimulant Medications
        1.2.7 Others
    1.3 Psychiatric and Nervous Drugs Segment by Application
        1.3.1 Global Psychiatric and Nervous Drugs Sales Comparison by Application: (2022-2028)
        1.3.2 Hospital Pharmacies
        1.3.3 Retail Pharmacies
        1.3.4 Online Pharmacies
    1.4 Global Psychiatric and Nervous Drugs Market Size Estimates and Forecasts
        1.4.1 Global Psychiatric and Nervous Drugs Revenue 2017-2028
        1.4.2 Global Psychiatric and Nervous Drugs Sales 2017-2028
        1.4.3 Psychiatric and Nervous Drugs Market Size by Region: 2017 Versus 2021 Versus 2028
2 Psychiatric and Nervous Drugs Market Competition by Manufacturers
    2.1 Global Psychiatric and Nervous Drugs Sales Market Share by Manufacturers (2017-2022)
    2.2 Global Psychiatric and Nervous Drugs Revenue Market Share by Manufacturers (2017-2022)
    2.3 Global Psychiatric and Nervous Drugs Average Price by Manufacturers (2017-2022)
    2.4 Manufacturers Psychiatric and Nervous Drugs Manufacturing Sites, Area Served, Product Type
    2.5 Psychiatric and Nervous Drugs Market Competitive Situation and Trends
        2.5.1 Psychiatric and Nervous Drugs Market Concentration Rate
        2.5.2 The Global Top 5 and Top 10 Largest Psychiatric and Nervous Drugs Players Market Share by Revenue
        2.5.3 Global Psychiatric and Nervous Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Psychiatric and Nervous Drugs Retrospective Market Scenario by Region
    3.1 Global Psychiatric and Nervous Drugs Retrospective Market Scenario in Sales by Region: 2017-2022
    3.2 Global Psychiatric and Nervous Drugs Retrospective Market Scenario in Revenue by Region: 2017-2022
    3.3 North America Psychiatric and Nervous Drugs Market Facts & Figures by Country
        3.3.1 North America Psychiatric and Nervous Drugs Sales by Country
        3.3.2 North America Psychiatric and Nervous Drugs Revenue by Country
        3.3.3 United States
        3.3.4 Canada
    3.4 Europe Psychiatric and Nervous Drugs Market Facts & Figures by Country
        3.4.1 Europe Psychiatric and Nervous Drugs Sales by Country
        3.4.2 Europe Psychiatric and Nervous Drugs Revenue by Country
        3.4.3 Germany
        3.4.4 France
        3.4.5 U.K.
        3.4.6 Italy
        3.4.7 Russia
    3.5 Asia Pacific Psychiatric and Nervous Drugs Market Facts & Figures by Region
        3.5.1 Asia Pacific Psychiatric and Nervous Drugs Sales by Region
        3.5.2 Asia Pacific Psychiatric and Nervous Drugs Revenue by Region
        3.5.3 China
        3.5.4 Japan
        3.5.5 South Korea
        3.5.6 India
        3.5.7 Australia
        3.5.8 China Taiwan
        3.5.9 Indonesia
        3.5.10 Thailand
        3.5.11 Malaysia
    3.6 Latin America Psychiatric and Nervous Drugs Market Facts & Figures by Country
        3.6.1 Latin America Psychiatric and Nervous Drugs Sales by Country
        3.6.2 Latin America Psychiatric and Nervous Drugs Revenue by Country
        3.6.3 Mexico
        3.6.4 Brazil
        3.6.5 Argentina
        3.6.6 Colombia
    3.7 Middle East and Africa Psychiatric and Nervous Drugs Market Facts & Figures by Country
        3.7.1 Middle East and Africa Psychiatric and Nervous Drugs Sales by Country
        3.7.2 Middle East and Africa Psychiatric and Nervous Drugs Revenue by Country
        3.7.3 Turkey
        3.7.4 Saudi Arabia
        3.7.5 UAE
4 Global Psychiatric and Nervous Drugs Historic Market Analysis by Type
    4.1 Global Psychiatric and Nervous Drugs Sales Market Share by Type (2017-2022)
    4.2 Global Psychiatric and Nervous Drugs Revenue Market Share by Type (2017-2022)
    4.3 Global Psychiatric and Nervous Drugs Price by Type (2017-2022)
5 Global Psychiatric and Nervous Drugs Historic Market Analysis by Application
    5.1 Global Psychiatric and Nervous Drugs Sales Market Share by Application (2017-2022)
    5.2 Global Psychiatric and Nervous Drugs Revenue Market Share by Application (2017-2022)
    5.3 Global Psychiatric and Nervous Drugs Price by Application (2017-2022)
6 Key Companies Profiled
    6.1 Pfizer
        6.1.1 Pfizer Corporation Information
        6.1.2 Pfizer Description and Business Overview
        6.1.3 Pfizer Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.1.4 Pfizer Psychiatric and Nervous Drugs Product Portfolio
        6.1.5 Pfizer Recent Developments/Updates
    6.2 Ely Lilly
        6.2.1 Ely Lilly Corporation Information
        6.2.2 Ely Lilly Description and Business Overview
        6.2.3 Ely Lilly Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.2.4 Ely Lilly Psychiatric and Nervous Drugs Product Portfolio
        6.2.5 Ely Lilly Recent Developments/Updates
    6.3 Actavis
        6.3.1 Actavis Corporation Information
        6.3.2 Actavis Description and Business Overview
        6.3.3 Actavis Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.3.4 Actavis Psychiatric and Nervous Drugs Product Portfolio
        6.3.5 Actavis Recent Developments/Updates
    6.4 Mylan
        6.4.1 Mylan Corporation Information
        6.4.2 Mylan Description and Business Overview
        6.4.3 Mylan Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.4.4 Mylan Psychiatric and Nervous Drugs Product Portfolio
        6.4.5 Mylan Recent Developments/Updates
    6.5 Randox
        6.5.1 Randox Corporation Information
        6.5.2 Randox Description and Business Overview
        6.5.3 Randox Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.5.4 Randox Psychiatric and Nervous Drugs Product Portfolio
        6.5.5 Randox Recent Developments/Updates
    6.6 Intellipharmaceutics
        6.6.1 Intellipharmaceutics Corporation Information
        6.6.2 Intellipharmaceutics Description and Business Overview
        6.6.3 Intellipharmaceutics Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.6.4 Intellipharmaceutics Psychiatric and Nervous Drugs Product Portfolio
        6.6.5 Intellipharmaceutics Recent Developments/Updates
    6.7 Astrazeneca
        6.6.1 Astrazeneca Corporation Information
        6.6.2 Astrazeneca Description and Business Overview
        6.6.3 Astrazeneca Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.4.4 Astrazeneca Psychiatric and Nervous Drugs Product Portfolio
        6.7.5 Astrazeneca Recent Developments/Updates
    6.8 Lundbeck
        6.8.1 Lundbeck Corporation Information
        6.8.2 Lundbeck Description and Business Overview
        6.8.3 Lundbeck Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.8.4 Lundbeck Psychiatric and Nervous Drugs Product Portfolio
        6.8.5 Lundbeck Recent Developments/Updates
    6.9 Allergan
        6.9.1 Allergan Corporation Information
        6.9.2 Allergan Description and Business Overview
        6.9.3 Allergan Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.9.4 Allergan Psychiatric and Nervous Drugs Product Portfolio
        6.9.5 Allergan Recent Developments/Updates
    6.10 GSK
        6.10.1 GSK Corporation Information
        6.10.2 GSK Description and Business Overview
        6.10.3 GSK Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.10.4 GSK Psychiatric and Nervous Drugs Product Portfolio
        6.10.5 GSK Recent Developments/Updates
    6.11 Otsuka Pharmaceutical
        6.11.1 Otsuka Pharmaceutical Corporation Information
        6.11.2 Otsuka Pharmaceutical Psychiatric and Nervous Drugs Description and Business Overview
        6.11.3 Otsuka Pharmaceutical Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.11.4 Otsuka Pharmaceutical Psychiatric and Nervous Drugs Product Portfolio
        6.11.5 Otsuka Pharmaceutical Recent Developments/Updates
    6.12 Takeda
        6.12.1 Takeda Corporation Information
        6.12.2 Takeda Psychiatric and Nervous Drugs Description and Business Overview
        6.12.3 Takeda Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.12.4 Takeda Psychiatric and Nervous Drugs Product Portfolio
        6.12.5 Takeda Recent Developments/Updates
    6.13 NHU Group
        6.13.1 NHU Group Corporation Information
        6.13.2 NHU Group Psychiatric and Nervous Drugs Description and Business Overview
        6.13.3 NHU Group Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.13.4 NHU Group Psychiatric and Nervous Drugs Product Portfolio
        6.13.5 NHU Group Recent Developments/Updates
    6.14 Shionogi
        6.14.1 Shionogi Corporation Information
        6.14.2 Shionogi Psychiatric and Nervous Drugs Description and Business Overview
        6.14.3 Shionogi Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.14.4 Shionogi Psychiatric and Nervous Drugs Product Portfolio
        6.14.5 Shionogi Recent Developments/Updates
    6.15 APOTEX
        6.15.1 APOTEX Corporation Information
        6.15.2 APOTEX Psychiatric and Nervous Drugs Description and Business Overview
        6.15.3 APOTEX Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.15.4 APOTEX Psychiatric and Nervous Drugs Product Portfolio
        6.15.5 APOTEX Recent Developments/Updates
    6.16 Chengdu Kanghong Pharmaceutical
        6.16.1 Chengdu Kanghong Pharmaceutical Corporation Information
        6.16.2 Chengdu Kanghong Pharmaceutical Psychiatric and Nervous Drugs Description and Business Overview
        6.16.3 Chengdu Kanghong Pharmaceutical Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.16.4 Chengdu Kanghong Pharmaceutical Psychiatric and Nervous Drugs Product Portfolio
        6.16.5 Chengdu Kanghong Pharmaceutical Recent Developments/Updates
    6.17 HUAHAI
        6.17.1 HUAHAI Corporation Information
        6.17.2 HUAHAI Psychiatric and Nervous Drugs Description and Business Overview
        6.17.3 HUAHAI Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.17.4 HUAHAI Psychiatric and Nervous Drugs Product Portfolio
        6.17.5 HUAHAI Recent Developments/Updates
    6.18 Zhejiang Jianfeng
        6.18.1 Zhejiang Jianfeng Corporation Information
        6.18.2 Zhejiang Jianfeng Psychiatric and Nervous Drugs Description and Business Overview
        6.18.3 Zhejiang Jianfeng Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.18.4 Zhejiang Jianfeng Psychiatric and Nervous Drugs Product Portfolio
        6.18.5 Zhejiang Jianfeng Recent Developments/Updates
    6.19 Beijing Winsunny Pharmaceutical
        6.19.1 Beijing Winsunny Pharmaceutical Corporation Information
        6.19.2 Beijing Winsunny Pharmaceutical Psychiatric and Nervous Drugs Description and Business Overview
        6.19.3 Beijing Winsunny Pharmaceutical Psychiatric and Nervous Drugs Sales, Revenue and Gross Margin (2017-2022)
        6.19.4 Beijing Winsunny Pharmaceutical Psychiatric and Nervous Drugs Product Portfolio
        6.19.5 Beijing Winsunny Pharmaceutical Recent Developments/Updates
7 Psychiatric and Nervous Drugs Manufacturing Cost Analysis
    7.1 Psychiatric and Nervous Drugs Key Raw Materials Analysis
       7.1.1 Key Raw Materials
       7.1.2 Key Suppliers of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
    7.3 Manufacturing Process Analysis of Psychiatric and Nervous Drugs
    7.4 Psychiatric and Nervous Drugs Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
    8.1 Marketing Channel
    8.2 Psychiatric and Nervous Drugs Distributors List
    8.3 Psychiatric and Nervous Drugs Customers
9 Psychiatric and Nervous Drugs Market Dynamics
    9.1 Psychiatric and Nervous Drugs Industry Trends
    9.2 Psychiatric and Nervous Drugs Market Drivers
    9.3 Psychiatric and Nervous Drugs Market Challenges
    9.4 Psychiatric and Nervous Drugs Market Restraints
10 Global Market Forecast
    10.1 Psychiatric and Nervous Drugs Market Estimates and Projections by Type
        10.1.1 Global Forecasted Sales of Psychiatric and Nervous Drugs by Type (2023-2028)
        10.1.2 Global Forecasted Revenue of Psychiatric and Nervous Drugs by Type (2023-2028)
    10.2 Psychiatric and Nervous Drugs Market Estimates and Projections by Application
        10.2.1 Global Forecasted Sales of Psychiatric and Nervous Drugs by Application (2023-2028)
        10.2.2 Global Forecasted Revenue of Psychiatric and Nervous Drugs by Application (2023-2028)
    10.3 Psychiatric and Nervous Drugs Market Estimates and Projections by Region
        10.3.1 Global Forecasted Sales of Psychiatric and Nervous Drugs by Region (2023-2028)
        10.3.2 Global Forecasted Revenue of Psychiatric and Nervous Drugs by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
    12.1 Methodology/Research Approach
        12.1.1 Research Programs/Design
        12.1.2 Market Size Estimation
        12.1.3 Market Breakdown and Data Triangulation
    12.2 Data Source
        12.2.1 Secondary Sources
        12.2.2 Primary Sources
    12.3 Author List
    12.4 Disclaimer
List of Tables
    Table 1. Global Psychiatric and Nervous Drugs Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million)
    Table 2. Global Psychiatric and Nervous Drugs Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million)
    Table 3. Global Psychiatric and Nervous Drugs Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
    Table 4. Global Psychiatric and Nervous Drugs Market Competitive Situation by Manufacturers in 2021
    Table 5. Global Psychiatric and Nervous Drugs Sales (K Units) of Key Manufacturers (2017-2022)
    Table 6. Global Psychiatric and Nervous Drugs Sales Market Share by Manufacturers (2017-2022)
    Table 7. Global Psychiatric and Nervous Drugs Revenue (US$ Million) by Manufacturers (2017-2022)
    Table 8. Global Psychiatric and Nervous Drugs Revenue Share by Manufacturers (2017-2022)
    Table 9. Global Market Psychiatric and Nervous Drugs Average Price (US$/Unit) of Key Manufacturers (2017-2022)
    Table 10. Manufacturers Psychiatric and Nervous Drugs Manufacturing Sites and Area Served
    Table 11. Manufacturers Psychiatric and Nervous Drugs Product Type
    Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 13. Global Psychiatric and Nervous Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Psychiatric and Nervous Drugs as of 2021)
    Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 15. Global Psychiatric and Nervous Drugs Sales by Region (2017-2022) & (K Units)
    Table 16. Global Psychiatric and Nervous Drugs Sales Market Share by Region (2017-2022)
    Table 17. Global Psychiatric and Nervous Drugs Revenue by Region (2017-2022) & (US$ Million)
    Table 18. Global Psychiatric and Nervous Drugs Revenue Market Share by Region (2017-2022)
    Table 19. North America Psychiatric and Nervous Drugs Sales by Country (2017-2022) & (K Units)
    Table 20. North America Psychiatric and Nervous Drugs Sales Market Share by Country (2017-2022)
    Table 21. North America Psychiatric and Nervous Drugs Revenue by Country (2017-2022) & (US$ Million)
    Table 22. North America Psychiatric and Nervous Drugs Revenue Market Share by Country (2017-2022)
    Table 23. Europe Psychiatric and Nervous Drugs Sales by Country (2017-2022) & (K Units)
    Table 24. Europe Psychiatric and Nervous Drugs Sales Market Share by Country (2017-2022)
    Table 25. Europe Psychiatric and Nervous Drugs Revenue by Country (2017-2022) & (US$ Million)
    Table 26. Europe Psychiatric and Nervous Drugs Revenue Market Share by Country (2017-2022)
    Table 27. Asia Pacific Psychiatric and Nervous Drugs Sales by Region (2017-2022) & (K Units)
    Table 28. Asia Pacific Psychiatric and Nervous Drugs Sales Market Share by Region (2017-2022)
    Table 29. Asia Pacific Psychiatric and Nervous Drugs Revenue by Region (2017-2022) & (US$ Million)
    Table 30. Asia Pacific Psychiatric and Nervous Drugs Revenue Market Share by Region (2017-2022)
    Table 31. Latin America Psychiatric and Nervous Drugs Sales by Country (2017-2022) & (K Units)
    Table 32. Latin America Psychiatric and Nervous Drugs Sales Market Share by Country (2017-2022)
    Table 33. Latin America Psychiatric and Nervous Drugs Revenue by Country (2017-2022) & (US$ Million)
    Table 34. Latin America Psychiatric and Nervous Drugs Revenue Market Share by Country (2017-2022)
    Table 35. Middle East and Africa Psychiatric and Nervous Drugs Sales by Country (2017-2022) & (K Units)
    Table 36. Middle East and Africa Psychiatric and Nervous Drugs Sales Market Share by Country (2017-2022)
    Table 37. Middle East and Africa Psychiatric and Nervous Drugs Revenue by Country (2017-2022) & (US$ Million)
    Table 38. Middle East and Africa Psychiatric and Nervous Drugs Revenue Market Share by Country (2017-2022)
    Table 39. Global Psychiatric and Nervous Drugs Sales by Type (2017-2022) & (K Units)
    Table 40. Global Psychiatric and Nervous Drugs Sales Market Share by Type (2017-2022)
    Table 41. Global Psychiatric and Nervous Drugs Revenue by Type (2017-2022) & (US$ Million)
    Table 42. Global Psychiatric and Nervous Drugs Revenue Share by Type (2017-2022)
    Table 43. Global Psychiatric and Nervous Drugs Price by Type (2017-2022) & (US$/Unit)
    Table 44. Global Psychiatric and Nervous Drugs Sales (K Units) by Application (2017-2022)
    Table 45. Global Psychiatric and Nervous Drugs Sales Market Share by Application (2017-2022)
    Table 46. Global Psychiatric and Nervous Drugs Revenue by Application (2017-2022) & (US$ Million)
    Table 47. Global Psychiatric and Nervous Drugs Revenue Share by Application (2017-2022)
    Table 48. Global Psychiatric and Nervous Drugs Price by Application (2017-2022) & (US$/Unit)
    Table 49. Pfizer Corporation Information
    Table 50. Pfizer Description and Business Overview
    Table 51. Pfizer Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 52. Pfizer Psychiatric and Nervous Drugs Product
    Table 53. Pfizer Recent Developments/Updates
    Table 54. Ely Lilly Corporation Information
    Table 55. Ely Lilly Description and Business Overview
    Table 56. Ely Lilly Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 57. Ely Lilly Psychiatric and Nervous Drugs Product
    Table 58. Ely Lilly Recent Developments/Updates
    Table 59. Actavis Corporation Information
    Table 60. Actavis Description and Business Overview
    Table 61. Actavis Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 62. Actavis Psychiatric and Nervous Drugs Product
    Table 63. Actavis Recent Developments/Updates
    Table 64. Mylan Corporation Information
    Table 65. Mylan Description and Business Overview
    Table 66. Mylan Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 67. Mylan Psychiatric and Nervous Drugs Product
    Table 68. Mylan Recent Developments/Updates
    Table 69. Randox Corporation Information
    Table 70. Randox Description and Business Overview
    Table 71. Randox Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 72. Randox Psychiatric and Nervous Drugs Product
    Table 73. Randox Recent Developments/Updates
    Table 74. Intellipharmaceutics Corporation Information
    Table 75. Intellipharmaceutics Description and Business Overview
    Table 76. Intellipharmaceutics Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 77. Intellipharmaceutics Psychiatric and Nervous Drugs Product
    Table 78. Intellipharmaceutics Recent Developments/Updates
    Table 79. Astrazeneca Corporation Information
    Table 80. Astrazeneca Description and Business Overview
    Table 81. Astrazeneca Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 82. Astrazeneca Psychiatric and Nervous Drugs Product
    Table 83. Astrazeneca Recent Developments/Updates
    Table 84. Lundbeck Corporation Information
    Table 85. Lundbeck Description and Business Overview
    Table 86. Lundbeck Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 87. Lundbeck Psychiatric and Nervous Drugs Product
    Table 88. Lundbeck Recent Developments/Updates
    Table 89. Allergan Corporation Information
    Table 90. Allergan Description and Business Overview
    Table 91. Allergan Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 92. Allergan Psychiatric and Nervous Drugs Product
    Table 93. Allergan Recent Developments/Updates
    Table 94. GSK Corporation Information
    Table 95. GSK Description and Business Overview
    Table 96. GSK Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 97. GSK Psychiatric and Nervous Drugs Product
    Table 98. GSK Recent Developments/Updates
    Table 99. Otsuka Pharmaceutical Corporation Information
    Table 100. Otsuka Pharmaceutical Description and Business Overview
    Table 101. Otsuka Pharmaceutical Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 102. Otsuka Pharmaceutical Psychiatric and Nervous Drugs Product
    Table 103. Otsuka Pharmaceutical Recent Developments/Updates
    Table 104. Takeda Corporation Information
    Table 105. Takeda Description and Business Overview
    Table 106. Takeda Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 107. Takeda Psychiatric and Nervous Drugs Product
    Table 108. Takeda Recent Developments/Updates
    Table 109. NHU Group Corporation Information
    Table 110. NHU Group Description and Business Overview
    Table 111. NHU Group Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 112. NHU Group Psychiatric and Nervous Drugs Product
    Table 113. NHU Group Recent Developments/Updates
    Table 114. Shionogi Corporation Information
    Table 115. Shionogi Description and Business Overview
    Table 116. Shionogi Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 117. Shionogi Psychiatric and Nervous Drugs Product
    Table 118. Shionogi Recent Developments/Updates
    Table 119. APOTEX Corporation Information
    Table 120. APOTEX Description and Business Overview
    Table 121. APOTEX Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 122. APOTEX Psychiatric and Nervous Drugs Product
    Table 123. APOTEX Recent Developments/Updates
    Table 124. Chengdu Kanghong Pharmaceutical Corporation Information
    Table 125. Chengdu Kanghong Pharmaceutical Description and Business Overview
    Table 126. Chengdu Kanghong Pharmaceutical Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 127. Chengdu Kanghong Pharmaceutical Psychiatric and Nervous Drugs Product
    Table 128. Chengdu Kanghong Pharmaceutical Recent Developments/Updates
    Table 129. HUAHAI Corporation Information
    Table 130. HUAHAI Description and Business Overview
    Table 131. HUAHAI Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 132. HUAHAI Psychiatric and Nervous Drugs Product
    Table 133. HUAHAI Recent Developments/Updates
    Table 134. Zhejiang Jianfeng Corporation Information
    Table 135. Zhejiang Jianfeng Description and Business Overview
    Table 136. Zhejiang Jianfeng Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 137. Zhejiang Jianfeng Psychiatric and Nervous Drugs Product
    Table 138. Zhejiang Jianfeng Recent Developments/Updates
    Table 139. Beijing Winsunny Pharmaceutical Corporation Information
    Table 140. Beijing Winsunny Pharmaceutical Description and Business Overview
    Table 141. Beijing Winsunny Pharmaceutical Psychiatric and Nervous Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 142. Beijing Winsunny Pharmaceutical Psychiatric and Nervous Drugs Product
    Table 143. Beijing Winsunny Pharmaceutical Recent Developments/Updates
    Table 144. Production Base and Market Concentration Rate of Raw Material
    Table 145. Key Suppliers of Raw Materials
    Table 146. Psychiatric and Nervous Drugs Distributors List
    Table 147. Psychiatric and Nervous Drugs Customers List
    Table 148. Psychiatric and Nervous Drugs Market Trends
    Table 149. Psychiatric and Nervous Drugs Market Drivers
    Table 150. Psychiatric and Nervous Drugs Market Challenges
    Table 151. Psychiatric and Nervous Drugs Market Restraints
    Table 152. Global Psychiatric and Nervous Drugs Sales Forecast by Type (2023-2028) & (K Units)
    Table 153. Global Psychiatric and Nervous Drugs Sales Market Share Forecast by Type (2023-2028)
    Table 154. Global Psychiatric and Nervous Drugs Revenue Forecast by Type (2023-2028) & (US$ Million)
    Table 155. Global Psychiatric and Nervous Drugs Revenue Market Share Forecast by Type (2023-2028)
    Table 156. Global Psychiatric and Nervous Drugs Sales Forecast by Application (2023-2028) & (K Units)
    Table 157. Global Psychiatric and Nervous Drugs Sales Market Share Forecast by Application (2023-2028)
    Table 158. Global Psychiatric and Nervous Drugs Revenue Forecast by Application (2023-2028) & (US$ Million)
    Table 159. Global Psychiatric and Nervous Drugs Revenue Market Share Forecast by Application (2023-2028)
    Table 160. Global Psychiatric and Nervous Drugs Sales Forecast by Region (2023-2028) & (K Units)
    Table 161. Global Psychiatric and Nervous Drugs Sales Market Share Forecast by Region (2023-2028)
    Table 162. Global Psychiatric and Nervous Drugs Revenue Forecast by Region (2023-2028) & (US$ Million)
    Table 163. Global Psychiatric and Nervous Drugs Revenue Market Share Forecast by Region (2023-2028)
    Table 164. Research Programs/Design for This Report
    Table 165. Key Data Information from Secondary Sources
    Table 166. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Psychiatric and Nervous Drugs
    Figure 2. Global Psychiatric and Nervous Drugs Market Share by Type in 2021 & 2028
    Figure 3. Antidepressants Product Picture
    Figure 4. Anti-anxiety Product Picture
    Figure 5. Antipsychotic Product Picture
    Figure 6. Mood Stabilizing Product Picture
    Figure 7. Stimulant Medications Product Picture
    Figure 8. Others Product Picture
    Figure 9. Global Psychiatric and Nervous Drugs Market Share by Application in 2021 & 2028
    Figure 10. Hospital Pharmacies
    Figure 11. Retail Pharmacies
    Figure 12. Online Pharmacies
    Figure 13. Global Psychiatric and Nervous Drugs Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 14. Global Psychiatric and Nervous Drugs Market Size (2017-2028) & (US$ Million)
    Figure 15. Global Psychiatric and Nervous Drugs Sales (2017-2028) & (K Units)
    Figure 16. Psychiatric and Nervous Drugs Sales Share by Manufacturers in 2021
    Figure 17. Global Psychiatric and Nervous Drugs Revenue Share by Manufacturers in 2021
    Figure 18. The Global 5 and 10 Largest Psychiatric and Nervous Drugs Players: Market Share by Revenue in 2021
    Figure 19. Psychiatric and Nervous Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
    Figure 20. Global Psychiatric and Nervous Drugs Sales Market Share by Region (2017-2022)
    Figure 21. Global Psychiatric and Nervous Drugs Sales Market Share by Region in 2021
    Figure 22. Global Psychiatric and Nervous Drugs Revenue Market Share by Region (2017-2022)
    Figure 23. Global Psychiatric and Nervous Drugs Revenue Market Share by Region in 2021
    Figure 24. United States Psychiatric and Nervous Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 25. Canada Psychiatric and Nervous Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 26. Germany Psychiatric and Nervous Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 27. France Psychiatric and Nervous Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 28. U.K. Psychiatric and Nervous Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 29. Italy Psychiatric and Nervous Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 30. Russia Psychiatric and Nervous Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 31. China Psychiatric and Nervous Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 32. Japan Psychiatric and Nervous Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 33. South Korea Psychiatric and Nervous Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 34. India Psychiatric and Nervous Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 35. Australia Psychiatric and Nervous Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 36. China Taiwan Psychiatric and Nervous Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 37. Indonesia Psychiatric and Nervous Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 38. Thailand Psychiatric and Nervous Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 39. Malaysia Psychiatric and Nervous Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 40. Mexico Psychiatric and Nervous Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 41. Brazil Psychiatric and Nervous Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 42. Argentina Psychiatric and Nervous Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 43. Colombia Psychiatric and Nervous Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 44. Turkey Psychiatric and Nervous Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 45. Saudi Arabia Psychiatric and Nervous Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 46. UAE Psychiatric and Nervous Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 47. Sales Market Share of Psychiatric and Nervous Drugs by Type (2017-2022)
    Figure 48. Manufacturing Cost Structure of Psychiatric and Nervous Drugs
    Figure 49. Manufacturing Process Analysis of Psychiatric and Nervous Drugs
    Figure 50. Psychiatric and Nervous Drugs Industrial Chain Analysis
    Figure 51. Channels of Distribution
    Figure 52. Distributors Profiles
    Figure 53. Bottom-up and Top-down Approaches for This Report
    Figure 54. Data Triangulation
    Figure 55. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Pfizer
Ely Lilly
Actavis
Mylan
Randox
Intellipharmaceutics
Astrazeneca
Lundbeck
Allergan
GSK
Otsuka Pharmaceutical
Takeda
NHU Group
Shionogi
APOTEX
Chengdu Kanghong Pharmaceutical
HUAHAI
Zhejiang Jianfeng
Beijing Winsunny Pharmaceutical
Frequently Asked Questions
Psychiatric and Nervous Drugs report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Psychiatric and Nervous Drugs report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Psychiatric and Nervous Drugs report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports